In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Biogen stock opened at $137.33 on Thursday. The company’s 50-day moving average price is $147.31 and its 200-day moving average price is $173.80. Biogen has a twelve month low of $128.51 and a ...

The firm owned 4,179 shares of the biotechnology company’s stock after acquiring an additional 423 shares during the period. Savant Capital LLC’s holdings in Biogen were worth $639,000 at the ...

The stock's fall snapped a seven-day winning streak.

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ ...

The company generated free cash flow of $722 million in Q4 and $2.7 billion for the year. Biogen issued downside guidance for 2025 with an EPS forecast between $15.25 to $16.25 versus $16.33.

Biogen on Tuesday agreed to pay $165 million upfront for exclusive rights to sell the drug, called zorevunersen, outside the U.S., Canada and Mexico. The company also agreed to split external ...

Following our analysis of the options activities associated with Biogen, we pivot to a closer look at the company's own performance. With a volume of 1,409,926, the price of BIIB is up 1.32% at ...